Articles tagged with Prostate Cancer
Researchers propose reevaluating nomenclature for low-grade prostate cancer, a condition that rarely metastasizes or causes symptoms. This shift aims to balance detection with treatment to reduce harms of overdiagnosis and overtreatment.
A multi-center phase III trial found photon- and proton-based radiation therapies to be similarly safe and effective in treating low- and intermediate-risk prostate cancer. Patients treated with either IMRT or proton therapy reported no significant differences in quality of life, tumor control, or progression-free survival.
UCLA investigators presented data on chemoradiotherapy in rectal cancer, MRI-guided radiotherapy for prostate cancer, and symptom self-reporting during treatment. Researchers developed a predictive model to identify patients most likely to respond to chemoradiotherapy in rectal cancer.
Researchers at Cold Spring Harbor Laboratory create a roadmap of how prostate cancer spreads throughout the body, showing that aggressive cells seed cancer's rare migrations to bones, liver, lungs, and lymph nodes. The new technology offers a clearer picture of cancer spread and could lead to more targeted therapeutics.
A new study has found that baseline testosterone, age, and duration of ADT are key predictors of testosterone recovery. The researchers developed a nomogram to estimate recovery times based on patient-specific characteristics, providing valuable insights for improving patient outcomes.
A new study by the University of Eastern Finland found that pro-inflammatory macrophages can transform prostate cancer cells into stem-like cells, making them resistant to treatment. The study reveals that these immune cells secrete factors that increase the expression of stem cell markers in prostate cancer cells.
A study published in Nature Communications found that the MYC gene is a common culprit driving prostate cancer progression. The research reveals how MYC activation attracts immune cells to the tumor but later helps hide it from immune detection, making it undetectable.
A new prostate biopsy technique, transperineal biopsy, has been shown to lower the risk of infection compared to traditional biopsies. The PREVENT trial found no infections among men who underwent the transperineal procedure, while those with traditional transrectal biopsies had a 1.6% infection rate despite receiving antibiotics.
A new study found that immunotherapy can effectively treat prostate cancer in men with a specific genetic type, slowing disease progression by four to 33 months. This treatment approach may be beneficial for approximately 4-5% of patients, who experience significant cancer control.
A new study by Michigan Medicine found that the Inflation Reduction Act's limit on Medicare Part D spending leads to significant savings for cancer patients prescribed oral chemotherapy. The average annual cost for these medications decreased from $11,284 in 2023 to $3,927 in 2024, resulting in median cost savings of $7,260.
A new AI model generates detailed images of cancer tissue that imitate what its staining would look like, reducing the need for resource-intensive lab analyses. The VirtualMultiplexer uses contrastive unpaired translation to create accurate virtual pictures of diagnostic tissue colorations.
A new study has identified NSD2 as a fundamental factor in early stages of prostate cancer development, found to alter androgen receptor function leading to rapid cell division and growth. The study may suggest a new way to therapeutically target prostate cancer by targeting the epigenetic component NSD2.
Researchers discovered that low testosterone levels stimulate cancer cell proliferation, while high doses cause differentiation and suppress growth. This finding could help physicians select patients for bi-polar androgen therapy, a technique using monthly high-dose testosterone injections.
Rates of prostate cancer across Europe more than doubled from 1990 to 2017, with highest increases in northern Europe, France, and the Baltic countries. Death rates were lower, sparking concerns about overdiagnosis and unnecessary treatment, emphasizing the need for carefully planned screening programs.
Researchers at HSE University discovered that the microRNA overexpression method may produce incorrect results due to errors in Dicer enzyme cleavage. This can lead to the formation of miRNA isoforms that target unintended genes, resulting in inaccurate conclusions about molecular mechanisms.
Researchers developed a novel compound to target prostate cancer using radioactive atom astatine-211, potentially overcoming issues with previous compounds like deastatination. The study found high accumulation in tumors and low accumulation in vital organs, highlighting the potential of this new compound for targeted alpha therapy.
Aston University researcher has developed a new method of analysing crystals in dehydrated blood samples using polarisation-based image reconstruction technique. The technique showed a 90% accuracy rate for early diagnosis and classification of cancer, making it less traumatic and risky for patients.
Researchers at Flinders University and University of South Australia have discovered a potential breakthrough in treating the most aggressive forms of prostate cancer using CDKI-73, a novel drug inhibitor. The study found that CDKI-73 effectively blocks the growth of prostate cancer cells while sparing normal cells.
Researchers investigated the connection between androgen deprivation therapy for prostate cancer and Alzheimer's disease. They found that ADT can exacerbate cognitive decline by increasing brain immune cell infiltration, but a combination with Natalizumab improved integrity of the blood-brain barrier and reduced inflammation.
A phase II clinical trial found that olaparib, a precision oncology drug, can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations. The study showed that 13 participants, including all 11 with BRCA2 mutations, had a decrease in PSA of at least 50% after treatment.
A new study published in Nature Medicine shows that precision therapy can improve survival for men with metastatic castration-resistant prostate cancer. The treatment, which involves analyzing the genetic profile of the tumor, has been shown to be more effective than chemotherapy in patients whose tumors have specific mutations.
Researchers at Mount Sinai have identified a new class of RNAs packed into tiny particles known as extracellular vesicles that could revolutionize how cancer and other diseases are diagnosed. These molecules undergo changes when cancer is present, suggesting their potential as biomarkers for detecting prostate cancer.
A new study suggests that MRI scans can help doctors identify patients with more aggressive prostate cancer, allowing for earlier treatment or active surveillance. The research found that suspicious lesions on an MRI test were associated with a higher risk of advanced disease in five years.
A new deep learning model detects clinically significant prostate cancer on MRI with performance comparable to experienced abdominal radiologists. The model's prediction can be used as an adjunct to improve diagnostic performance and reduce false positives.
Researchers have developed an AI-based system that can predict the risk of prostate cancer more accurately than traditional methods. The new tool combines MRI images and deep learning to identify low-risk patients who may not need a biopsy, potentially sparing them from unnecessary procedures and reducing complications.
Researchers from the University of Sheffield have developed a new form of immunotherapy using nanoparticles that delays the onset of resistance to hormone therapy in prostate cancer. This innovative approach stimulates immune cells called T cells to attack cancer cells, marking a significant breakthrough in treating prostate cancer.
Researchers highlight acute need for mental health services and support for men with prostate cancer. The study found that 15% of prostate cancer patients started anti-anxiety and antidepression medications at diagnosis, while only 6% sought help from mental health services.
A new study from Michigan Medicine suggests that inhibiting the SWI/SNF epigenetic complex can therapeutically target oncogenic transcription factors. The research, led by Arul Chinnaiyan, builds on previous work to find genetic vulnerabilities in transcription factor-driven cancers.
A recent review article highlights the importance of genetic testing for men carrying BRCA1 or BRCA2 mutations, which increase their risk of developing prostate, pancreatic, and breast cancers. The guidelines emphasize the need for personalized cancer screening to help identify high-risk individuals.
Researchers at UCLA Health Sciences identified three distinct patient preference-based profiles among men with low-risk prostate cancer. Despite differences in preferences, physician recommendations played a crucial role in determining treatment choices. The study highlights the need for better integrating patient preferences into trea...
Researchers found that lower doses of radiopharmaceutical therapy approaches for metastatic castrate-resistant prostate cancer were just as effective as the standard dose, with better tolerability among patients. The study showed improved PSA response rates and comparable median overall survival in both groups.
A recent study published in Journal of Clinical Oncology has shown that the Stockholm3 prostate cancer blood test is equally effective in detecting clinically significant cancer across different ethnic groups, including African Americans and Asians. The test reduces unnecessary biopsies by 45% while maintaining high detection rates.
Researchers from Radboud University Medical Center discuss the potential of using early on-treatment circulating tumor DNA measurements as a response assessment for metastatic castration-resistant prostate cancer. The detection of ctDNA at baseline and 4-weeks after treatment initiation can predict response durability to first-line ARPIs.
Researchers found that out-of-pocket costs for additional tests, including MRI and biopsies, are common and increasing among privately insured men with high PSA results. The median cost rose substantially between 2010-2020, deterring patients from undergoing recommended screening.
A cross-sectional study found that men from disadvantaged neighborhoods had higher stress-related gene expression in their prostate tumors. This association suggests a potential link between neighborhood factors and aggressive prostate cancer.
A study found that living in disadvantaged neighborhoods is associated with higher stress-related gene activity, which could contribute to aggressive prostate cancer in African American men. The research also linked five genes related to inflammation to an increased risk of prostate cancer.
Researchers identified two risk factors that indicate higher risk of aggressive prostate cancer, including high PSA levels and positive biopsy samples. Patients with these indicators are at increased risk of adverse pathology, early recurrence, and death.
Researchers developed a novel liquid biopsy technique to monitor disease evolution in metastatic prostate cancer patients. The method analyzes DNA and RNA in circulating extracellular vesicles, capturing tumor genomics and transcriptomic changes.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center have received a $1.8 million grant to advance personalized cancer therapy for prostate cancer patients. They aim to predict and prevent long-term side effects from radiation treatment, improving quality of life for men diagnosed with the disease.
Pharmacogenomics (PGx) testing can predict how patients will respond to systemic therapies, enabling personalized treatment plans and optimizing medication dosages. A specific gene variant, HSD3B1, has been linked to castration-resistant prostate cancer progression.
Researchers at Osaka University have developed molecules that can correct improper splicing of a vital tumor suppressor gene in neuroendocrine cancers. The study demonstrates that these splice-switching oligonucleotides can significantly reduce viable cancer cells and tumor size in mice, suggesting a novel therapeutic approach for intr...
A new study has identified potential cancer drivers hidden in so-called 'junk' regions of DNA, which could lead to early diagnosis and new treatments. The discovery reveals mutations in previously overlooked regions of the genome that may contribute to the formation and progression of at least 12 different cancers.
A phase 2 study found fluorine-18 PSMA-1007 PET/computed tomography to be superior to multiparametric MRI for locoregional staging of prostate cancer. The technology supports its use in the preoperative workflow for intermediate-risk and high-risk tumors.
Researchers explore the feasibility of deep learning models in segmenting lesions on PET/CT images to improve salvage radiation therapy planning for prostate cancer. The study demonstrates promising potential to reduce inter- and intra-observer variations, leading to more accurate treatment outcomes.
A recent study published in JAMA found that transgender women on hormone therapy have drastically lower PSA levels, which may lead to delayed diagnosis and treatment of prostate cancer. The researchers analyzed Veterans Health Administration records and recommended caution when interpreting PSA values in transgender women.
Current prostate cancer screening guidelines may not be effective for transgender women taking estrogen, as it can lower PSA levels, making it difficult to detect early-stage cancer. The study aims to provide more appropriate screening guidelines for this population.
Xiaohu Xia's research focuses on enhancing diagnostic efficacy of enzyme-linked immunosorbent assay (ELISA) testing using specially tailored nickel-platinum nanoparticles. His goal is to improve disease detection accuracy by more than 300 times, enabling early diagnosis of cancers like prostate and colorectal cancer.
Scientists have identified a new mechanism by which cells counteract a key cancer-promoting protein using an 'invisible' protein called RAI2. In cancer cell lines and patient samples, RAI2 levels are reduced in more severe and treatment-resistant forms of prostate cancer.
Ternarx aims to unlock the potential of targeted protein degrader (TPD) technology to treat hard-to-treat cancers like neuroblastoma and prostate cancer. The company will initially focus on developing new treatments for these diseases using novel TPD technology.
A recent study published in The Lancet Oncology found that an AI system can detect prostate cancer nearly seven percent more significantly than a group of radiologists using MRI scans. Additionally, the AI identifies suspicious areas less often, potentially reducing unnecessary biopsies by half.
A new AI model has been shown to significantly improve the accuracy of diagnosing prostate cancer by 45 times compared to doctors' measurements alone. The system assists in mapping out the boundaries of cancerous tissue, reducing the risk of underestimation and enabling more precise treatment planning and effective surgical procedures.
A new chelator, L804, reduces off-target toxicity in PSMA radiopharmaceutical therapy by improving the bond between radioactive metal ions and targeting antibodies. This makes the therapy safer and more effective for patients.
[177Lu]Lu-PSMA-617 significantly improves radiographic progression-free survival and overall quality of life for patients with taxane-naive mCRPC, while minimizing adverse events. The study's findings suggest that [177Lu]Lu-PSMA-617 may change the treatment paradigm for pre-taxane advanced prostate cancer patients.
A glowing marker dye attached to a special marker molecule enables surgeons to visualize prostate cancer cells in real-time, allowing for more precise removal of cancerous tissues and preservation of healthy tissue. This technology has the potential to reduce the chances of cancer recurrence and minimize life-changing side effects.
Researchers identify UBE2J1's role in degrading the androgen receptor, a key player in prostate cancer progression. The study suggests targeting this ubiquitination machinery may help overcome antiandrogen resistance in cancer therapy.
The University of Oklahoma has been awarded a $1.2 million grant to lead a Phase 1B clinical trial for the treatment of prostate cancer when it begins to spread beyond the prostate. The trial combines two existing drugs, relugolix and enzalutamide, which may provide more effective treatments for aggressive prostate cancer patients.
Researchers identified protein JUN as a potential therapeutic option to slow tumor growth in prostate cancer, contradicting previous findings that linked high JUN levels to increased tumor growth. The study showed that JUN slows tumor progression and improves immune response, providing a new starting point for therapy development.
This population-based study found that higher PSA screening prevalence was associated with lower odds of advanced disease and prostate cancer-specific mortality among men with prostate cancer. Associations varied by age, race and ethnicity, and U.S. Census region.
A cost-effectiveness analysis found that first-line MRI-based screening for prostate cancer is less effective and more costly than first-line PSA testing. Despite free MRI costs, the first-line approach resulted in increased false positives and overdiagnosis without substantial reductions in mortality.
Researchers found that increased activity of the SIX2 protein contributes to increased cell plasticity and treatment resistance in prostate cancer cells. Silencing the SIX2 gene reduces malignancy and cancer spread in hormone therapy-resistant types of cancer.